Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study

Joris J. Komen, Anton Pottegård, Aukje K. Mantel-Teeuwisse, Tomas Forslund, Paul Hjemdahl, Björn Wettermark, Jesper Hallas, Morten Olesen, Marion Bennie, Tanja Mueller, Raymond Carragher, Øystein Karlstad, Lars J. Kjerpeseth, Olaf H. Klungel*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)
1 Downloads (Pure)


Aims: There is currently no consensus on whether atrial fibrillation (AF) patients at low risk for stroke (one non-sex-related CHA2DS2-VASc point) should be treated with an oral anticoagulant. 

Methods and results: We conducted a multi-country cohort study in Sweden, Denmark, Norway, and Scotland. In total, 59 076 patients diagnosed with AF at low stroke risk were included. We assessed the rates of stroke or major bleeding during treatment with a non-vitamin K antagonist oral anticoagulant (NOAC), a vitamin K antagonist (VKA), or no treatment, using inverse probability of treatment weighted (IPTW) Cox regression. In untreated patients, the rate for ischaemic stroke was 0.70 per 100 person-years and the rate for a bleed was also 0.70 per 100 person-years. Comparing NOAC with no treatment, the stroke rate was lower [hazard ratio (HR) 0.72; 95% confidence interval (CI) 0.56-0.94], and the rate for intracranial haemorrhage (ICH) was not increased (HR 0.84; 95% CI 0.54-1.30). Comparing VKA with no treatment, the rate for stroke tended to be lower (HR 0.81; 95% CI 0.59-1.09), and the rate for ICH tended to be higher during VKA treatment (HR 1.37; 95% CI 0.88-2.14). Comparing NOAC with VKA treatment, the rate for stroke was similar (HR 0.92; 95% CI 0.70-1.22), but the rate for ICH was lower during NOAC treatment (HR 0.63; 95% CI 0.42-0.94). 

Conclusion: These observational data suggest that NOAC treatment may be associated with a positive net clinical benefit compared with no treatment or VKA treatment in patients at low stroke risk, a question that can be tested through a randomized controlled trial.

Original languageEnglish
Pages (from-to)3528-3538
Number of pages11
JournalEuropean Heart Journal
Issue number37
Early online date10 Mar 2022
Publication statusPublished - 1 Oct 2022
Externally publishedYes


  • atrial fibrillation
  • non-vitamin K antagonist oral anticoagulants
  • stroke risk
  • vitamin K antagonists


Dive into the research topics of 'Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study'. Together they form a unique fingerprint.

Cite this